Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN
Woodley Farra Manion Portfolio Management Inc. decreased its stake in AstraZeneca PLC by 1.0% in the third quarter of last year, holding 752,814 shares valued at $57.76 million. Despite this slight reduction, other institutional investors have increased their positions in AZN. Analysts have largely maintained a "Buy" or "Overweight" rating on AstraZeneca, with an average target price of $95.75, and the company recently announced a dividend payment.
Vanguard Group Inc. Acquires 39,929 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Vanguard Group Inc. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by acquiring an additional 39,929 shares in the third quarter, bringing its total holdings to 23,291,224 shares valued at approximately $2.29 billion. Zimmer Biomet recently reported strong quarterly earnings, beating analyst estimates with $2.42 EPS and $2.24 billion in revenue, and announced a quarterly dividend of $0.24. Institutional investors collectively own 88.89% of the stock, which analysts currently rate as a "Hold" with an average target price of $106.20.
Skandinaviska Enskilda Banken AB publ Has $6.12 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Zimmer Biomet Holdings, Inc. (ZBH) by 47.5%, now holding 62,079 shares valued at $6.12 million. This move follows Zimmer Biomet exceeding Q3 earnings expectations and providing strong FY2026 guidance. The stock currently carries a consensus "Hold" rating from analysts with an average price target of $106.20, despite mixed analyst actions including downgrades and upgrades.
William Blair Initiates Zimmer Biomet Holdings at Market Perform
William Blair has initiated coverage of Zimmer Biomet Holdings (ZBH) with a Market Perform rating. This announcement is amidst several recent analyst adjustments to price targets and ratings for the medical equipment company, following its Q4 2025 earnings call where it beat quarterly estimates on strong implant demand.
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More
The global stem cell and regenerative therapy market is projected to grow significantly from $16.7 billion in 2025 to $43.8 billion by 2030, driven by technological advancements and increased investments. This growth is fueled by the potential of these therapies to address various chronic health conditions such as cancer, Parkinson's, and diabetes. The market report provides a comprehensive analysis of trends, revenue forecasts, segmentation, and profiles of leading companies like Gilead Sciences, Novartis, and Bristol-Myers Squibb.
William Blair initiates Zimmer Biomet stock rating at Market Perform
William Blair has initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a Market Perform rating, noting the medical device company's efforts in divestitures and acquisitions have led to 7.2% revenue growth and a 72% gross profit margin over the last year. The firm is impressed with Zimmer Biomet's strengthened product lineup and pipeline, with InvestingPro analysis suggesting the stock is undervalued and expects net income growth this year. William Blair will monitor the progress of a planned U.S. commercial organization transition and its impact on sales, especially given the crucial sales representative and surgeon relationships in the orthopedics sector.
William Blair initiates Zimmer Biomet stock rating at Market Perform
William Blair has initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a Market Perform rating, citing the company's efforts in divestitures, acquisitions, and strengthening its product lineup, which has led to 7.2% revenue growth and a 72% gross profit margin. The firm will monitor the execution of a planned U.S. commercial organization transition before adopting a more constructive view. Zimmer Biomet recently reported strong Q4 earnings, though they issued a cautious outlook for 2026.
ZIMMER BIOMET HOLDINGS, INC. SEC 10-K Report
Zimmer Biomet Holdings, Inc. has released its 2025 Form 10-K report, detailing significant financial and operational performance, including a 7.2% increase in net sales to $8,231.5 million. The report highlights strategic acquisitions, new product launches like the ZBEdge Platform, and ongoing investments in R&D, while also addressing market, operational, and regulatory challenges. The company anticipates 2.5% to 4.5% net sales growth in 2026 and plans to continue returning value to shareholders through dividends and share repurchases.
Factory Mutual Insurance Co. Acquires Shares of 57,852 AstraZeneca PLC $AZN
Factory Mutual Insurance Co. has acquired 57,852 shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, valued at approximately $4.438 million. AstraZeneca recently announced a dividend of $1.595 per share, payable on March 23rd, with a record date of February 20th and an ex-dividend date also on February 20th, representing a dividend yield of 153.0%. The company's stock opened at $208.76, has a market cap of $323.77 billion, and an average analyst rating of "Moderate Buy" with a target price of $95.75.
Neurosurgery Market Is Going to Boom |Medtronic, Stryker Corporation, Zimmer Biomet, Johnson & Johnson
The global neurosurgery market is projected to grow from USD 4.10 billion in 2026 to USD 5.69 billion by 2033, exhibiting a CAGR of 4.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report by Coherent Market Insights provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
KLAR DEADLINE ALERT: Hagens Berman Notifies Klarna Group plc (KLAR) Investors of Today's Lead Plaintiff Deadline in IPO Securities Class Action
Hagens Berman is alerting investors of Klarna Group plc (NYSE: KLAR) about the February 20, 2026, lead plaintiff deadline in a securities class action. The lawsuit alleges that Klarna's September 2025 IPO documents were misleading by emphasizing strong credit modeling while omitting aggressive lending to financially unsophisticated consumers, including for high-risk items. Shortly after the IPO, Klarna reported a 102% increase in credit loss provisions, causing shares to drop significantly below the IPO price.
Robotic Surgical Systems Market Is Going to Boom | Intuitive
Coherent Market Insights has published a new research report on the Robotic Surgical Systems Market, forecasting substantial growth from 2026 to 2033. The report offers a deep dive into market trends, drivers, and competitive landscapes, featuring key players like Intuitive Surgical, Medtronic, and Johnson & Johnson. It provides comprehensive segmentation, regional analysis, and strategic insights for businesses in the healthcare sector.
AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board
Ontario Teachers Pension Plan Board significantly reduced its stake in AstraZeneca PLC by 41.0% in Q3 2025, selling 569,294 shares, though AstraZeneca remains one of its largest holdings. Meanwhile, other institutional investors like CIBC World Market, Y Intercept Hong Kong, and Oxbow Advisors increased their positions in the company. AstraZeneca recently announced a dividend of $1.595 per share, payable March 23, and analysts maintain a "Moderate Buy" rating with an average price target of $95.75.
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
This article recommends avoiding Zimmer Biomet Holdings Inc (ZBH) due to disappointing long-term revenue growth, slim projected revenue growth, and unimpressive past growth initiatives as indicated by a low Return on Invested Capital. The stock's valuation is considered reasonable, but the author believes there are better investment opportunities available. The article suggests exploring other high-quality stocks with strong market-beating returns.
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
This article advises investors to avoid Zimmer Biomet Holdings Inc (ZBH) due to disappointing long-term revenue growth, slim projected revenue growth, and inefficient growth initiatives. Instead, it suggests looking for other high-quality stocks that offer better potential. The article highlights that ZBH's current valuation is reasonable, but its weak fundamentals present too much downside risk.
Zimmer Biomet Launches Advancement for Hindfoot Fusion
Zimmer Biomet, through its subsidiary Paragon 28, has launched the Phantom® Curved TTC Nail System for hindfoot fusion. This innovative system features a curved design that mimics the natural anatomy of the hindfoot, aiming to provide stronger fixation, more reproducible alignment, and better soft-tissue preservation compared to traditional straight nails. The device offers clinical advantages such as no required plantar incision, increased calcaneal bone contact, and built-in torsional stability, making it suitable for both primary and revision TTC fusion procedures.
ZBH Investor Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and "Inconsistent" Execution
Hagens Berman is investigating Zimmer Biomet (ZBH) after the company's stock price dropped 15% following disclosures of distributor order cancellations in emerging markets and a significant revenue miss in Latin America. The investigation focuses on whether Zimmer Biomet's senior management misled investors regarding the stability of its international business, especially after providing "high confidence" assurances for 2025 revenue targets. The law firm is encouraging investors who suffered losses to come forward.
ZBH Investor Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and "Inconsistent" Execution
Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) following concerns about the reasonable basis for its 2025 revenue targets. The investigation focuses on whether ZBH senior management misled investors regarding the stability of its international business, particularly after assurances of "very high" confidence in growth were followed by disclosures of distributor order cancellations in emerging markets and a significant revenue miss, leading to a 15% stock drop. The firm is urging investors who suffered losses to report them for a potential securities class action lawsuit.
PNC Financial Services Group Inc. Raises Stock Position in AstraZeneca PLC $AZN
PNC Financial Services Group Inc. significantly increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.1% during the third quarter, acquiring an additional 9,904 shares to hold a total of 250,986 shares valued at $19.256 million. AstraZeneca recently declared a dividend of $1.595 per share, payable on March 23rd, with the ex-dividend date set for February 20th. The stock currently trades around $209.39, boasting a market capitalization of $324.74 billion, and has a consensus "Moderate Buy" rating from analysts with an average target price of $95.75.
ZBH Investor Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and "Inconsistent" Execution
Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) following disclosures that challenge the basis of the company's previously stated "high confidence" in its 2025 revenue targets. The investigation focuses on whether Zimmer Biomet senior management misled investors after the company revealed distributor order cancellations and a significant revenue miss in Latin America, despite earlier assurances of strong international growth. This news caused a 15% stock drop and led the CEO to admit the need for "far more measured" external commentary.
Medtronic completes first U.S. cases with Hugo
Medtronic has announced the successful completion of the first U.S. commercial cases utilizing its Hugo soft-tissue robotic surgery system. Dr. Jihad Kaouk of Cleveland Clinic performed a robotic-assisted prostatectomy, marking a significant step following FDA clearance for urologic procedures late last year. This move positions Medtronic to challenge Intuitive's longstanding dominance in the U.S. soft-tissue surgical robotics market, with CEO Geoff Martha expressing optimism about future expansions into additional indications.
Medtronic gets FDA nod for Infuse bone graft in TLIF procedures
Medtronic announced that its Infuse bone graft received FDA premarket approval for use in TLIF (transforaminal lumbar interbody fusion) procedures at one or two levels from L2-S1, making it the only growth factor bone graft with PMA for ALIF, OLIF, and TLIF. The approval is supported by clinical data from 493 patients, showing fusion rates exceeding 90% in single-level TLIF and strong results in two-level constructs. This expansion offers surgeons a highly validated option for complex fusion cases, enhancing treatment tailoring for individual patient needs.
Zimmer Biomet, Paragon 28 announce commercial launch of curved TTC nail system
Zimmer Biomet and 28 announced the commercial launch of their new Phantom curved TTC nail system, expanding Zimmer Biomet's foot and ankle portfolio following the acquisition of Paragon 28. This next-generation system features a curved design that follows the anatomic arc of the foot, aiming to improve alignment reproducibility, increase torsional stability, and preserve soft tissue compared to traditional straight TTC nails. The launch reinforces Zimmer Biomet's commitment to Paragon 28's innovative orthopedic technology, supporting various TTC fusion procedures.
The Top 5 Analyst Questions From Zimmer Biomet's Q4 Earnings Call
Zimmer Biomet's Q4 earnings exceeded expectations, driven by strong U.S. execution and new product demand, particularly in knee and hip implants. CEO Ivan Tornos highlighted gains in robotics and double-digit growth in cranio-maxillofacial and upper extremities. Despite positive Q4 results, analysts questioned cautious guidance due to a planned U.S. salesforce transition, pricing erosion, and the integration of acquisitions like Paragon 28.
NeuroOne Reports Fiscal Q1 2026 Financial Results
NeuroOne Medical Technologies Corporation has released its financial results for the first quarter of fiscal year 2026, reporting product revenue of $2.9 million and a net loss of $1.4 million. Despite a slight year-over-year decrease in product revenue, the company achieved significant milestones including FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System and expansion of its intellectual property portfolio. NeuroOne projects product revenue of at least $10.5 million for fiscal year 2026 and aims for commercial availability of its drug delivery system by the end of the third quarter.
There May Be Reason For Hope In Zimmer Biomet Holdings' (NYSE:ZBH) Disappointing Earnings
Despite Zimmer Biomet Holdings (NYSE:ZBH) reporting soft profit numbers, the market reacted positively due to underlying signs of promise. The company's statutory profit was reduced by US$470m due to unusual items, which are generally non-recurring and could lead to improved future profitability. Analysts' forecasts suggest an optimistic outlook for the company's future earnings.
Intuitive Surgical Stock: 2025 Q4 Results & 2026 Outlook - News and Statistics
Intuitive Surgical underperformed the broader market and healthcare equipment ETF despite strong Q4 2025 earnings, with revenue up 19% to $2.87 billion, driven by increased procedure volumes and da Vinci system placements. For 2026, the company forecasts 13-15% da Vinci procedure growth and analysts project a 13.9% rise in EPS to $8.22, maintaining a "Moderate Buy" consensus rating.
Intragastric Balloons Market to Reach $115.3 Million, Globally, by 2033 at 13.6% CAGR: Allied Market Research
The global intragastric balloons market, valued at $32.2 million in 2023, is projected to reach $115.3 million by 2033, growing at a CAGR of 13.6%. This growth is primarily driven by rising obesity rates, increased preference for non-surgical weight-loss options, and technological advancements. Key market segments include single intragastric balloons, saline-filled balloons, and hospitals as the main end-users, with North America leading in utilization and Asia-Pacific showing rapid growth.
NeuroOne (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne (NMTC) reported its Q1 2026 earnings, detailing a sequential increase in product revenue but a net loss compared to the prior year due to the absence of license revenue. The company highlighted significant progress with its 1RF brain ablation system and trigeminal nerve ablation system, along with advancements in drug delivery and lower back pain programs. NeuroOne also announced a positive fiscal 2026 revenue outlook, projecting at least a 17% increase in sales.
ABN Amro Investment Solutions Sells 11,020 Shares of Zimmer Biomet Holdings, Inc. $ZBH
ABN Amro Investment Solutions recently reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 31.6%, selling 11,020 shares, and now holds 23,860 shares valued at approximately $2.35 million. This move comes as Zimmer Biomet reported strong quarterly results, surpassing EPS and revenue expectations, and provided encouraging FY2026 guidance. Despite ABN Amro's reduction, institutional interest remains high, with Rakuten Investment Management Inc. opening a significant new position.
3 Reasons to Avoid NVST and 1 Stock to Buy Instead
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
ResMed (RMD) shares have underperformed the S&P 500 significantly over the last six months, prompting investors to reevaluate the stock. The company shows positive attributes including consistent currency revenue growth, strong long-term EPS growth, and an increasing free cash flow margin. Despite its recent drawdown, ResMed's stock trades at 21.1x forward P/E, leading to questions about its current buying opportunity.
Stryker’s New Humerus System Deepens Trauma Platform And Surgeon Ties
Stryker has launched the T2 Alpha Humerus Nailing System, a new trauma solution utilizing its SOMA technology to enhance efficiency and consistency in humerus fracture procedures. This strategic product release aims to standardize complex upper extremity trauma care for hospitals and surgeons, reinforcing Stryker's established presence in orthopedics. For investors, this move is seen as a way to deepen hospital relationships and surgeon loyalty, rather than a driver of short-term stock fluctuations.
Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance
This article states that Zimmer Biomet exceeded expectations for Q4. However, the company adopted a measured tone regarding its 2026 guidance, indicating a cautious outlook despite recent performance.
Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance
Zimmer Biomet exceeded its fourth-quarter expectations but presented cautious guidance for 2026. The company's performance indicates strong Q4 results, though its outlook for the upcoming year suggests a measured approach to future growth or potential challenges.
Medtronic wins FDA nod for surgical robot for spine procedures
Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS robotic system for spine surgery in the U.S. This system integrates planning, navigation, and robotics into a single platform and is designed for use in both hospitals and ambulatory surgery centers. A key innovation is the LiveAlign sentimental tracking feature, which allows surgeons to visualize real-time anatomic motion and patient alignment without repeated imaging, aiding in more consistent execution of surgical plans.
Cibc World Market Inc. Lowers Stake in Parker-Hannifin Corporation $PH
Cibc World Market Inc. has reduced its stake in Parker-Hannifin Corporation by 17% in the third quarter of 2025, selling 3,458 shares and now holding 16,910 shares valued at $12.82 million. This move comes as company insiders have also been selling shares, totaling 5,825 shares worth $5.39 million over the past 90 days. Despite the institutional and insider selling, Parker-Hannifin reported strong quarterly earnings, beating EPS expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $990.47, while the company also declared a $1.80 quarterly dividend.
Skylands Capital LLC Sells 20,100 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Skylands Capital LLC significantly reduced its stake in Zimmer Biomet Holdings, Inc. by selling 20,100 shares, decreasing its position by 84.2%. Despite this, Zimmer Biomet reported strong Q4 results, surpassing earnings estimates and announcing a new share buyback program. The company also provided optimistic guidance for FY2026 adjusted EPS, and institutional investors collectively hold a substantial majority of its stock.
embecta names new Chairman of the Board and Lead Independent Director
Embecta Corp. (Nasdaq: EMBC) has announced new leadership appointments to its Board of Directors. Devdatt "Dev" Kurdikar has been elected as Chairman of the Board, and Dr. Claire Pomeroy has been appointed as Lead Independent Director, effective immediately. These changes follow the retirement of LTG (Ret.) David F. Melcher, the previous Non-Executive Chairman.
ZBH.SW Zimmer Biomet (SIX) at CHF67.50 pre-market on volume spike: Feb 2026 outlook
Zimmer Biomet (ZBH.SW) saw a significant pre-market volume spike, trading at CHF67.50 on the SIX exchange in February 2026, marking a -4.26% drop from its prior close and hitting a year low. Meyka AI rates ZBH.SW with a B+ (BUY) grade, but its model forecasts a potential downside of -16.00% over 12 months, projecting a price of CHF56.70. Traders are advised to monitor the CHF67.50 support level and the 50-day average at CHF78.58 for short-term technical improvements.
New blanket-like MRI device aims to make scans less stressful for kids
Philips (NYSE: PHG) announced the availability of InkSpace Imaging’s Snuggle™ pediatric body array coil for its 3.0T MRI systems, which received FDA 510(k) clearance. This flexible, blanket-like device aims to enhance comfort for children during MRI exams while providing high-resolution imaging and improving clinical workflow efficiency. The Snuggle coil is currently available in the United States, with plans for broader regional rollout.
Sound Shore Management Inc CT Decreases Stake in Zimmer Biomet Holdings, Inc. $ZBH
Sound Shore Management Inc CT reduced its stake in Zimmer Biomet Holdings, Inc. by 3.3% in the third quarter, now holding 896,284 shares valued at $88.3 million. Despite a Q4 earnings beat and a new share buyback program, the medical equipment provider issued cautious FY2026 guidance, citing potential headwinds. Analyst consensus is a "Hold" with a $106.45 price target, while institutional investors own nearly 89% of the company.
Johnson Investment Counsel Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Johnson Investment Counsel Inc. significantly reduced its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 38.3% in the third quarter, selling 17,924 shares and valuing its remaining holdings at $2.85 million. Despite this, other institutional investors increased their positions, and analysts have mixed ratings on the stock, with an average "Hold" and a consensus price target of $106.45. Zimmer Biomet recently reported strong Q4 earnings, beating estimates with $2.42 EPS and $2.24 billion in revenue, and announced a new share repurchase program.
Zimmer Biomet (ZBH) Margin Compression And One Off Loss Test Bullish Growth Narrative
Zimmer Biomet (ZBH) concluded FY 2025 with revenue of US$8.2 billion and a net profit margin of 8.6%, a decrease from 11.8% the previous year, partly due to a one-off loss of US$263.3 million. Despite analyst expectations for 18% annual earnings growth driven by investments in robotics and digital health, revenue growth was 3.6%. The company's valuation signals, including a P/E ratio below industry averages and a DCF fair value significantly higher than its current share price, are weighed against its high debt level and recent margin compression, creating a conflicting picture for investors.
embecta CEO Dev Kurdikar adds chair role as Pomeroy becomes lead director
Embecta (Nasdaq: EMBC) has announced significant board leadership changes, effective February 11, 2026. Devdatt "Dev" Kurdikar, the current President and CEO, has been elected Chairman of the Board, while Dr. Claire Pomeroy has been elected Lead Independent Director. These changes follow the retirement of LTG (Ret.) David F. Melcher and are part of embecta's ongoing transformation into a broader medical supplies company.
embecta names new Chairman of the Board and Lead Independent Director
Embecta Corp. has announced the appointment of Devdatt Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director. These changes follow the retirement of former Non-Executive Chairman, LTG (Ret.) David F. Melcher. Both Kurdikar and Pomeroy expressed confidence in leading embecta's transformation into a broader medical supplies company.
Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced
Zimmer Biomet (ZBH) reported strong fourth-quarter and full-year 2025 sales, with Q4 sales reaching US$2,243.8 million, despite a decline in quarterly net income. The company also announced a new US$1,500 million share repurchase program, reinforcing its commitment to shareholder returns. While sales growth was robust, softer 2026 guidance shifts focus to execution on its U.S. sales force overhaul and managing potential margin pressures from pricing and integration costs.
Rothschild & Co Redburn Adjusts Zimmer Biomet PT to $115 From $125, Maintains Buy Rating
Rothschild & Co Redburn has revised its price target for Zimmer Biomet Holdings, Inc. (ZBH) from $125 to $115, while reaffirming a "Buy" rating on the stock. This adjustment comes amidst a flurry of analyst activity, with several other firms also updating their price targets for Zimmer Biomet. The company recently reported its Q4 2025 earnings, beating estimates on strong implant demand and announcing a $1.5 billion equity buyback plan.
ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum
Zimmer Biomet (ZBH) reported strong Q4 CY2025 results, exceeding revenue expectations, driven by product momentum and U.S. execution. However, the company issued cautious 2026 guidance due to a planned overhaul of its U.S. salesforce, which is expected to cause short-term disruption but lead to long-term growth. Management highlighted new product adoption, robotics gains, and international growth, while acknowledging near-term pressure on operating margins from investments and pricing.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. reported strong Q4 2025 results, with organic constant currency sales growth of 5.4% and EPS of $2.42, exceeding expectations. The company is undergoing a significant transformation of its U.S. sales force to enhance specialization and productivity, which is expected to cause some short-term disruption but drive long-term mid-single-digit growth. For 2026, Zimmer Biomet forecasts organic constant currency revenue growth of 1% to 3% and adjusted EPS of $8.30 to $8.45, with a continued focus on innovation and leveraging its dedicated sales channel.
